The present invention relates to pyridazin-4(1H)-one derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
We designed and synthesised a series of novel CYP51 inhibitors. Three rounds of structural optimisation and modification obtained compound C6 which showed superior antifungal activity.